New obesity drug AMG 513 enters first human safety tests

NCT ID NCT06585462

First seen Feb 15, 2026 · Last updated May 21, 2026 · Updated 17 times

Summary

This early-stage study tests a new drug called AMG 513 in 80 adults with obesity to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor side effects and drug levels in the blood. The goal is to gather initial safety data before larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMETABOLIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anaheim Clinical Trials

    RECRUITING

    Anaheim, California, 92801, United States

  • Carilion Medical Center

    RECRUITING

    Lake Forest, California, 92630, United States

  • Clinical Pharmacology of Miami, LLC

    RECRUITING

    Miami, Florida, 33172, United States

  • Fomat Medical Research

    RECRUITING

    Oxnard, California, 93030, United States

  • Translational Clinical Research LLC

    RECRUITING

    Aventura, Florida, 33180, United States

Conditions

Explore the condition pages connected to this study.